Skip to content

Deployment of dedicated nursing staff to stimulate use of clozapine.

Deployment of dedicated nursing staff to stimulate use of clozapine.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON20244
Enrollment
16
Registered
2015-04-28
Start date
2015-06-04
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-affective psychotic disorder. Niet-affectieve psychotische stoornis. Titel: Deployment of dedicated nursing staff to stimulate use of clozapine. Hypothese: Physicians in teams of Type/Condition A (where they can delegate clozapine monitoring tasks to a Nurse Practitioner) will prescribe clozapine more often than physicians in teams of Type/Condition B (where they should performing monitoring tasks themselves). Blindering: Single-blind Primaire uitkomst: Proportion of patients indic

Interventions

1. Education of physicians and NPs about indications for clozapine. 2. Physicians and NPs screen all patients in their team for a possible indication for clozapine. 3. Randomization of teams into con

Sponsors

Rivierduinen, GGZ Leiden, the Netherlands and Maastricht University, the Netherlands.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Teams: - Outpatient teams in which a nurse practitioner participates Patients: - Age 18-55 - Diagnosis: non-affective psychotic disorder

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

MeasureTime frame
1a. Proportion of missed weekly lab exams (white blood cells) in condition A vs. B. 1b. Number of days the lab exams (white blood cells) are delayed, divided by total number of required lab exams in condition A vs. B.

Secondary

MeasureTime frame
1. Duration of clozapine use in condition A vs. B. 2. Clinical Global Impression-Schizophrenia scale (CGI-SCH) score of change in condition A vs. B. 3. Proportion of patients indicated for clozapine (in condition A vs. B) who actually start with this drug. 4. Proportion of patients for whom clozapine is indicated. 5. Qualitative data to explore how potentially hazardous side-effects were handled.

Contacts

Public ContactYvonne van der Zalm

GGZ Leiden

y.vanderzalm@ggzleiden.nl06-11519672

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)